{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:23:58Z","timestamp":1786983838038,"version":"build-2736575974"},"reference-count":107,"publisher":"Elsevier","isbn-type":[{"value":"9780323915267","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016230","name":"Steven and Alexandra Cohen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA07209"],"award-info":[{"award-number":["T32DA07209"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.apha.2021.10.003","type":"book-chapter","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T21:46:36Z","timestamp":1648158396000},"page":"105-132","source":"Crossref","is-referenced-by-count":11,"title":["Human behavioral pharmacology of psychedelics"],"prefix":"10.1016","member":"78","reference":[{"issue":"23","key":"10.1016\/bs.apha.2021.10.003_bb0010","doi-asserted-by":"crossref","first-page":"8053","DOI":"10.1523\/JNEUROSCI.0383-12.2012","article-title":"Dissociable influences of opiates and expectations on pain","volume":"32","author":"Atlas","year":"2012","journal-title":"Journal of Neuroscience"},{"issue":"10","key":"10.1016\/bs.apha.2021.10.003_bb0015","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s00213-018-4981-x","article-title":"Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Effects on cognition","volume":"235","author":"Barrett","year":"2018","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/bs.apha.2021.10.003_bb0020","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"Journal of Psychopharmacology"},{"issue":"10","key":"10.1016\/bs.apha.2021.10.003_bb0025","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","article-title":"Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers","volume":"86","author":"Bershad","year":"2019","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1016\/bs.apha.2021.10.003_bb0030","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"Journal of Psychopharmacology"},{"issue":"10","key":"10.1016\/bs.apha.2021.10.003_bb0035","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.biopsych.2008.12.009","article-title":"Ambience and drug choice: Cocaine- and heroin-taking as a function of environmental context in humans and rats","volume":"65","author":"Caprioli","year":"2009","journal-title":"Biological Psychiatry"},{"issue":"12","key":"10.1016\/bs.apha.2021.10.003_bb0040","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"Journal of Psychopharmacology"},{"issue":"8","key":"10.1016\/bs.apha.2021.10.003_bb0045","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00213-020-05533-9","article-title":"Subjective features of the psilocybin experience that may account for its self-administration by humans: A double-blind comparison of psilocybin and dextromethorphan","volume":"237","author":"Carbonaro","year":"2020","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0050","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00213-017-4769-4","article-title":"Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Similarities and differences in subjective experiences","volume":"235","author":"Carbonaro","year":"2018","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/bs.apha.2021.10.003_bb0055","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"15","key":"10.1016\/bs.apha.2021.10.003_bb0060","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/bs.apha.2021.10.003_bb0065","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1017\/S0033291715002901","article-title":"The paradoxical psychological effects of lysergic acid diethylamide (LSD)","volume":"46","author":"Carhart-Harris","year":"2016","journal-title":"Psychological Medicine"},{"key":"10.1016\/bs.apha.2021.10.003_bb0070","series-title":"Results from the 2019 National Survey on drug use and health: Detailed tables","author":"Center for Behavioral Health Statistics and Quality","year":"2020"},{"key":"10.1016\/bs.apha.2021.10.003_bb0075","doi-asserted-by":"crossref","first-page":"577","DOI":"10.15288\/qjsa.1959.20.577","article-title":"Use of d-lysergic acid diethylamide in the treatment of alcoholism","volume":"20","author":"Chwelos","year":"1959","journal-title":"Quarterly Journal of Studies on Alcohol"},{"issue":"5","key":"10.1016\/bs.apha.2021.10.003_bb0080","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/bs.apha.2021.10.003_bb0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ASCs) in humans","volume":"31","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/bs.apha.2021.10.003_bb0090","first-page":"1","article-title":"Pahnke's \u201cgood Friday experiment\u201d: A long-term follow-up and methodological critique","volume":"23","author":"Doblin","year":"1991","journal-title":"Journal of Transpersonal Psychology"},{"issue":"10","key":"10.1016\/bs.apha.2021.10.003_bb0095","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40262-017-0513-9","article-title":"Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects","volume":"56","author":"Dolder","year":"2017","journal-title":"Clinical Pharmacokinetics"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0100","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/shm\/hkl039","article-title":"\u2018Hitting highs at rock bottom\u2019: LSD treatment for alcoholism, 1950\u20131970","volume":"19","author":"Dyck","year":"2006","journal-title":"Social History of Medicine"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/02791072.1997.10400190","article-title":"Set, setting, and matrix","volume":"29","author":"Eisner","year":"1997","journal-title":"Journal of Psychoactive Drugs"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00008877-200403000-00007","article-title":"Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys","volume":"15","author":"Fantegrossi","year":"2004","journal-title":"Behavioural Pharmacology"},{"issue":"6","key":"10.1016\/bs.apha.2021.10.003_bb0115","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1360-0443.2004.00744.x","article-title":"Comparison of acute lethal toxicity of commonly abused psychoactive substances","volume":"99","author":"Gable","year":"2004","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/bs.apha.2021.10.003_bb0120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881121991822","article-title":"Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches","volume":"35","author":"Garcia-Romeu","year":"2021","journal-title":"Journal of Psychopharmacology"},{"issue":"7","key":"10.1016\/bs.apha.2021.10.003_bb0125","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"The Journal of Nervous and Mental Disease"},{"issue":"1","key":"10.1016\/bs.apha.2021.10.003_bb0130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2015","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2021.10.003_bb0135","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaclp.2020.12.012","article-title":"A \"trip\" to the intensive care unit: An intravenous injection of psilocybin","volume":"62","author":"Giancola","year":"2021","journal-title":"Journal of the Academy of Consultation-Liaison Psychiatry"},{"issue":"1","key":"10.1016\/bs.apha.2021.10.003_bb0140","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s002130050860","article-title":"Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study","volume":"142","author":"Gouzoulis-Mayfrank","year":"1999","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/bs.apha.2021.10.003_bb0145","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2021.10.003_bb0150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors","volume":"32","author":"Griffiths","year":"2018","journal-title":"Journal of Psychopharmacology"},{"issue":"4","key":"10.1016\/bs.apha.2021.10.003_bb0155","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/bs.apha.2021.10.003_bb0160","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2021.10.003_bb0165","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2021.10.003_bb0170","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1016\/bs.apha.2021.10.003_bb0175","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: A midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum","year":"2018","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/bs.apha.2021.10.003_bb0180","article-title":"Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy","author":"Gukasyan","year":"2021","journal-title":"Transcultural Psychiatry"},{"issue":"12","key":"10.1016\/bs.apha.2021.10.003_bb0185","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2021.10.003_bb0190","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/cpt.2057","article-title":"Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participants","volume":"109","author":"Holze","year":"2021","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"3","key":"10.1016\/bs.apha.2021.10.003_bb0195","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","volume":"46","author":"Holze","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2021.10.003_bb0200","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","article-title":"Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects","volume":"45","author":"Holze","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/bs.apha.2021.10.003_bb0205","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2021.10.003_bb0210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"American Journal of Drug and Alcohol Abuse"},{"issue":"3","key":"10.1016\/bs.apha.2021.10.003_bb0215","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential therapeutic effects of psilocybin","volume":"14","author":"Johnson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/bs.apha.2021.10.003_bb0220","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.apha.2021.10.003_bb0225","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"issue":"6","key":"10.1016\/bs.apha.2021.10.003_bb0230","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: Guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"1\u20133","key":"10.1016\/bs.apha.2021.10.003_bb0235","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drugalcdep.2011.10.029","article-title":"Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers","volume":"123","author":"Johnson","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/bs.apha.2021.10.003_bb0240","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41598-021-81446-7","article-title":"Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing","volume":"11","author":"Kaertner","year":"2021","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/bs.apha.2021.10.003_bb0245","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/BF01575629","article-title":"Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide","volume":"41","author":"Kast","year":"1967","journal-title":"Psychiatric Quarterly"},{"key":"10.1016\/bs.apha.2021.10.003_bb0250","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1213\/00000539-196405000-00013","article-title":"Study of lysergic acid diethylamide as an analgesic agent","volume":"43","author":"Kast","year":"1964","journal-title":"Anesthesia & Analgesia"},{"issue":"11","key":"10.1016\/bs.apha.2021.10.003_bb0255","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.biopsych.2012.04.005","article-title":"Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors","volume":"72","author":"Kometer","year":"2012","journal-title":"Biological Psychiatry"},{"issue":"25","key":"10.1016\/bs.apha.2021.10.003_bb0260","doi-asserted-by":"crossref","first-page":"10544","DOI":"10.1523\/JNEUROSCI.3007-12.2013","article-title":"Activation of serotonin 2A receptors underlies the psilocybin-induced effects on \u03b1 oscillations, N170 visual-evoked potentials, and visual hallucinations","volume":"33","author":"Kometer","year":"2013","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/bs.apha.2021.10.003_bb0265","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3389\/fphar.2017.00814","article-title":"LSD increases primary process thinking via serotonin 2a receptor activation","volume":"8","author":"Kraehenmann","year":"2017","journal-title":"Frontiers in Pharmacology"},{"issue":"7","key":"10.1016\/bs.apha.2021.10.003_bb0270","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"Journal of Psychopharmacology"},{"issue":"11","key":"10.1016\/bs.apha.2021.10.003_bb0275","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","article-title":"Psychedelic drugs in biomedicine","volume":"38","author":"Kyzar","year":"2017","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/bs.apha.2021.10.003_bb0280","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00005053-196312000-00007","article-title":"Reactions to psilocybin administered in a supportive environment","volume":"137","author":"Leary","year":"1963","journal-title":"Journal of Nervous and Mental Disorders"},{"issue":"1","key":"10.1016\/bs.apha.2021.10.003_bb0285","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2190\/UUCL-E5V6-XC25-5MC6","article-title":"Illustrating caffeine's pharmacological and expectancy effects utilizing a balanced placebo design","volume":"26","author":"Lotshaw","year":"1996","journal-title":"Journal of Drug Education"},{"issue":"11","key":"10.1016\/bs.apha.2021.10.003_bb0290","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/0269881111420188","article-title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness","volume":"25","author":"MacLean","year":"2011","journal-title":"Journal of Psychopharmacology"},{"issue":"4","key":"10.1016\/bs.apha.2021.10.003_bb0295","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1468-5906.2012.01685.x","article-title":"Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin","volume":"51","author":"MacLean","year":"2012","journal-title":"Journal of the Scientific Study of Religion"},{"issue":"5","key":"10.1016\/bs.apha.2021.10.003_bb0300","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1139\/cjr31-097","article-title":"A synthesis of the methyltryptamines and some derivatives","volume":"5","author":"Manske","year":"1931","journal-title":"Canadian Journal of Research"},{"key":"10.1016\/bs.apha.2021.10.003_bb0305","first-page":"159","article-title":"Cognitive processes in alcohol use: Expectancy and the balanced placebo design","volume":"1","author":"Marlatt","year":"1980","journal-title":"Advances in Substance Abuse: Behavioral biological research"},{"issue":"4","key":"10.1016\/bs.apha.2021.10.003_bb0310","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00213-012-2740-y","article-title":"Balanced placebo design with marijuana: Pharmacological and expectancy effects on impulsivity and risk taking","volume":"223","author":"Metrik","year":"2012","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/bs.apha.2021.10.003_bb0315","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1037\/a0016502","article-title":"Effectiveness of a marijuana expectancy manipulation: Piloting the balanced-placebo design for marijuana","volume":"17","author":"Metrik","year":"2009","journal-title":"Experimental & Clinical Psychopharmacology"},{"issue":"6","key":"10.1016\/bs.apha.2021.10.003_bb0320","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1016\/bs.apha.2021.10.003_bb0325","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/a-1312-7297","article-title":"Psychedelics and psychotherapy","volume":"54","author":"Nayak","year":"2021","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"10.1016\/bs.apha.2021.10.003_bb0330","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1177\/0269881118780713","article-title":"High dose psilocybin is associated with positive subjective effects in healthy volunteers","volume":"32","author":"Nicholas","year":"2018","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0335","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacological Reviews"},{"issue":"7","key":"10.1016\/bs.apha.2021.10.003_bb0340","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/0269881118780612","article-title":"Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts","volume":"32","author":"Noorani","year":"2018","journal-title":"Journal of Psychopharmacology"},{"issue":"9752","key":"10.1016\/bs.apha.2021.10.003_bb0345","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: A multicriteria decision analysis","volume":"376","author":"Nutt","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0350","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","article-title":"The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects","volume":"4","author":"Olson","year":"2020","journal-title":"ACS Pharmacology & Translational Science"},{"issue":"5","key":"10.1016\/bs.apha.2021.10.003_bb0355","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00213-020-05464-5","article-title":"Tripping on nothing: Placebo psychedelics and contextual factors","volume":"237","author":"Olson","year":"2020","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2021.10.003_bb0360","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report","volume":"37","author":"Os\u00f3rio Fde","year":"2015","journal-title":"Brazilian Journal of Psychiatry"},{"issue":"4","key":"10.1016\/bs.apha.2021.10.003_bb0365","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/02791072.2001.10399925","article-title":"Pharmepena-psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N, N-dimethyl-tryptamine","volume":"33","author":"Ott","year":"2001","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/bs.apha.2021.10.003_bb0370","series-title":"Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness: A thesis","author":"Pahnke","year":"1963"},{"issue":"4","key":"10.1016\/bs.apha.2021.10.003_bb0375","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychological Medicine"},{"issue":"4","key":"10.1016\/bs.apha.2021.10.003_bb0380","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addiction Biology"},{"issue":"3","key":"10.1016\/bs.apha.2021.10.003_bb0385","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/02791072.1979.10472103","article-title":"Voluntary drug self-administration by nonhumans: A review","volume":"11","author":"Poling","year":"1979","journal-title":"Journal of Psychedelic Drugs"},{"issue":"3","key":"10.1016\/bs.apha.2021.10.003_bb0390","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2a receptor activation","volume":"27","author":"Preller","year":"2017","journal-title":"Current Biology"},{"issue":"3","key":"10.1016\/bs.apha.2021.10.003_bb0395","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/npp.2011.228","article-title":"Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers","volume":"37","author":"Quednow","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/bs.apha.2021.10.003_bb0400","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/dta.1685","article-title":"Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: A comparative study","volume":"7","author":"Riba","year":"2015","journal-title":"Drug Testing and Analysis"},{"issue":"1","key":"10.1016\/bs.apha.2021.10.003_bb0405","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s002130000606","article-title":"Subjective effects and tolerability of the south American psychoactive beverage Ayahuasca in healthy volunteers","volume":"154","author":"Riba","year":"2001","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2021.10.003_bb0410","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/jpet.103.049882","article-title":"Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics","volume":"306","author":"Riba","year":"2003","journal-title":"Journal of Pharmacology and Experimental Theapeutics"},{"issue":"8","key":"10.1016\/bs.apha.2021.10.003_bb0415","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0420","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0306-4603(81)90003-4","article-title":"The balanced placebo design: Methodological considerations","volume":"6","author":"Rohsenow","year":"1981","journal-title":"Addictive Behaviors"},{"issue":"12","key":"10.1016\/bs.apha.2021.10.003_bb0425","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0430","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2466\/pr0.1962.10.2.383","article-title":"Drugs and placebos: A model design","volume":"10","author":"Ross","year":"1962","journal-title":"Psychological Reports"},{"issue":"1","key":"10.1016\/bs.apha.2021.10.003_bb0435","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study","volume":"36","author":"Sanches","year":"2016","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"6","key":"10.1016\/bs.apha.2021.10.003_bb0440","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study","volume":"28","author":"Savage","year":"1973","journal-title":"Archives of General Psychiatry"},{"issue":"8","key":"10.1016\/bs.apha.2021.10.003_bb0445","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","article-title":"Acute effects of lysergic acid diethylamide in healthy subjects","volume":"78","author":"Schmid","year":"2015","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0450","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00213-017-4733-3","article-title":"Long-lasting subjective effects of LSD in normal subjects","volume":"235","author":"Schmid","year":"2018","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2021.10.003_bb0455","doi-asserted-by":"crossref","first-page":"469","DOI":"10.15288\/qjsa.1966.27.469","article-title":"A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior","volume":"27","author":"Smart","year":"1966","journal-title":"Quarterly Journal of Studies on Alcohol"},{"issue":"6","key":"10.1016\/bs.apha.2021.10.003_bb0460","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00005053-197312000-00002","article-title":"The use of LSD in time-limited psychotherapy","volume":"157","author":"Soskin","year":"1973","journal-title":"Journal of Nervous and Mental Disorders"},{"key":"10.1016\/bs.apha.2021.10.003_bb0465","series-title":"Psilocybin mushrooms of the world","author":"Stamets","year":"1996"},{"issue":"4","key":"10.1016\/bs.apha.2021.10.003_bb0470","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881120959609","article-title":"Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans","volume":"35","author":"Stenb\u00e6k","year":"2021","journal-title":"Journal of Psychopharmacology"},{"issue":"1\u20132","key":"10.1016\/bs.apha.2021.10.003_bb0475","first-page":"121","article-title":"Human psychopharmacology of N,N-dimethyltryptamine","volume":"73","author":"Strassman","year":"1996","journal-title":"Behavioural Brain Research"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0480","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","article-title":"Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects","volume":"51","author":"Strassman","year":"1994","journal-title":"Archives of General Psychiatry"},{"issue":"9","key":"10.1016\/bs.apha.2021.10.003_bb0485","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/0006-3223(95)00200-6","article-title":"Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans","volume":"39","author":"Strassman","year":"1996","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0490","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","article-title":"Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale","volume":"51","author":"Strassman","year":"1994","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0495","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1021\/acsptsci.0c00187","article-title":"Set and setting: A randomized study of different musical genres in supporting psychedelic therapy","volume":"4","author":"Strickland","year":"2020","journal-title":"ACS Pharmacology & Translational Science"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030800","article-title":"Prediction of psilocybin response in healthy volunteers","volume":"7","author":"Studerus","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/bs.apha.2021.10.003_bb0505","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0510","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1530-0277.2006.00039.x","article-title":"Understanding alcohol expectancy effects: Revisiting the placebo condition","volume":"30","author":"Testa","year":"2006","journal-title":"Alcoholism: Clinical and Experimental Research"},{"issue":"3","key":"10.1016\/bs.apha.2021.10.003_bb0515","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","article-title":"Psilocybin--summary of knowledge and new perspectives","volume":"24","author":"Tyl\u0161","year":"2014","journal-title":"European Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/bs.apha.2021.10.003_bb0520","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.euroneuro.2016.03.012","article-title":"Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans","volume":"26","author":"Valle","year":"2016","journal-title":"European Neuropsychopharmacology"},{"issue":"17","key":"10.1016\/bs.apha.2021.10.003_bb0525","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"issue":"19","key":"10.1016\/bs.apha.2021.10.003_bb0530","first-page":"100","article-title":"Seeking the magic mushroom","volume":"42","author":"Wasson","year":"1957","journal-title":"Life"},{"key":"10.1016\/bs.apha.2021.10.003_bb0535","series-title":"The wondrous mushroom. Mycolatry in mesoamerica","author":"Wasson","year":"1980"},{"issue":"2","key":"10.1016\/bs.apha.2021.10.003_bb0540","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The subjective effects of psychedelics are necessary for their enduring therapeutic effects","volume":"4","author":"Yaden","year":"2020","journal-title":"ACS Pharmacology & Translational Science"}],"container-title":["Advances in Pharmacology","Behavioral Pharmacology of Drug Abuse: Current Status"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358921000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358921000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:27:48Z","timestamp":1762360068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358921000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323915267"],"references-count":107,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2021.10.003","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}